At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CLLS Cellectis SA
Market Closed 12-20 16:00:00 EST
1.64
+0.05
+3.14%
盘后1.64
+0.000.00%
16:00 EST
High1.64
Low1.53
Vol87.89K
Open1.58
D1 Closing1.59
Amplitude6.92%
Mkt Cap164.15M
Tradable Cap117.20M
Total Shares100.09M
T/O139.33K
T/O Rate0.12%
Tradable Shares71.46M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
European Equities Traded in the US as American Depositary Receipts Tumble in Friday Trading; Down 4.6% for Week
Press Release: Cellectis announces the drawdown of the third tranche of EUR5 million under the credit facility agreement entered with the European Investment Bank (EIB)
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates. The company is developing ALLO-715 and ALLO-605 for the treatment of multiple myeloma; ALLO-501 to treat large B-cell lymphoma; ALLO-316, an allogeneic engineered CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small cell lung cancer; and ALLO-182 to treat gastric and pancreatic cancer. It also develops UCART22 for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia; UCART123 to treat acute myeloid leukemia; UCART 20x22 for relapsed or refractory B-Cell non-hodgkin's lymphoma; and cema-cel to treat relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics, Inc.; and joint research and collaboration, and investment agreement with AstraZeneca Holdings B.V., as well as with AstraZeneca Ireland Limited. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.